sulfasalazine has been researched along with Colorectal Neoplasms in 17 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SSZ) is an anti-inflammatory drug that has been demonstrated to induce apoptosis and tumor regression through inhibition of plasma membrane cystine transporter xc(-)." | 5.42 | Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. ( Chen, G; Hu, Y; Huang, P; Lu, WH; Ma, MZ; Song, M; Wang, P; Wen, S; Xu, RH; Yang, J; Zhu, CF, 2015) |
| "The purpose of the study was to assess whether folic acid supplementation and long term therapy with sulfasalazine can reduce the risk of colorectal cancer (CRC) development in longstanding extensive ulcerative colitis." | 4.82 | Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence. ( Becheanu, G; Ciocîrlan, M; Croitoru, A; Diculescu, M; Piţigoi, D; Spanache, S, 2003) |
| "Long-term sulfasalazine administration reduced proliferative CD44v9(+) cells and increased the degree of differentiation of adenocarcinomas." | 3.83 | Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer. ( Hasegawa, H; Kameyama, K; Kitagawa, Y; Nagano, O; Okabayashi, K; Saya, H; Seishima, R; Shimoda, M; Tsuruta, M, 2016) |
| " Other data collected included history of primary sclerosing cholangitis, family history of colorectal cancer, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate)." | 3.72 | Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. ( Forbes, A; Kamm, M; Price, A; Rumbles, S; Rutter, M; Saunders, B; Schofield, G; Talbot, I; Wilkinson, K; Williams, C, 2004) |
| " It has recently been suggested that presence of primary sclerosing cholangitis is another independent risk factor-especially for proximal colorectal dysplasia or cancer-and that treatment with sulfasalazine might reduce the frequency of colorectal cancer in ulcerative colitis; the present study was undertaken to shed light on the validity of these theories." | 3.71 | Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. ( Broomé, U; Lindberg, BU; Persson, B, 2001) |
| "Mesalamine was associated with a modest reduction in the odds ratio (OR) of CRN (OR = 0." | 2.52 | Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. ( Akbari, M; Moss, AC; OʼConnor, A; Packey, CD, 2015) |
| "ulcerative colitis and Crohn's disease), for both active disease and the control of remission." | 2.44 | Drug insight: aminosalicylates for the treatment of IBD. ( Munck, LK; Nielsen, OH, 2007) |
| "Sulfasalazine (SSZ) is an anti-inflammatory drug that has been demonstrated to induce apoptosis and tumor regression through inhibition of plasma membrane cystine transporter xc(-)." | 1.42 | Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. ( Chen, G; Hu, Y; Huang, P; Lu, WH; Ma, MZ; Song, M; Wang, P; Wen, S; Xu, RH; Yang, J; Zhu, CF, 2015) |
| " The underlying mechanism for TL-118-treatment success was associated with hepatic perfusion attenuation resulting from reduced nitric-oxide (NO) serum levels as elucidated by using hemodynamic response imaging (HRI, a functional MRI combined with hypercapnia and hyperoxia)." | 1.38 | Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. ( Abramovitch, R; Corchia, N; Edrei, Y; Gross, E, 2012) |
| "The risk of colorectal cancer was not increased, either in the total group of patients or in patients with colonic Crohn's disease exclusively (standardized morbidity ratio, 1." | 1.32 | Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. ( Binder, V; Jess, T; Langholz, E; Munkholm, P; Winther, KV, 2004) |
| "The risk of colorectal cancer increases in patients with ulcerative colitis, most markedly among young patients and/or those with extensive disease at onset." | 1.29 | Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. ( Adami, HO; Baron, J; Ekbom, A; Pinczowski, D; Yuen, J, 1994) |
| "The mean duration of ulcerative colitis before diagnosis was 7." | 1.29 | Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. ( Jayanthi, V; Mac Kay, H; Mayberry, JF; Moody, GA; Probert, CS, 1996) |
| "A regional inception cohort of 1161 ulcerative colitis (UC) patients was followed up from diagnosis to the end of 1987." | 1.28 | Colorectal cancer risk and mortality in patients with ulcerative colitis. ( Binder, V; Davidsen, M; Langholz, E; Munkholm, P, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, MZ | 1 |
| Chen, G | 1 |
| Wang, P | 1 |
| Lu, WH | 1 |
| Zhu, CF | 1 |
| Song, M | 1 |
| Yang, J | 1 |
| Wen, S | 1 |
| Xu, RH | 1 |
| Hu, Y | 1 |
| Huang, P | 1 |
| OʼConnor, A | 1 |
| Packey, CD | 1 |
| Akbari, M | 1 |
| Moss, AC | 1 |
| Seishima, R | 1 |
| Okabayashi, K | 1 |
| Nagano, O | 1 |
| Hasegawa, H | 1 |
| Tsuruta, M | 1 |
| Shimoda, M | 1 |
| Kameyama, K | 1 |
| Saya, H | 1 |
| Kitagawa, Y | 1 |
| Edrei, Y | 1 |
| Gross, E | 1 |
| Corchia, N | 1 |
| Abramovitch, R | 1 |
| Diculescu, M | 1 |
| Ciocîrlan, M | 2 |
| Piţigoi, D | 1 |
| Becheanu, G | 1 |
| Croitoru, A | 1 |
| Spanache, S | 1 |
| Rutter, M | 1 |
| Saunders, B | 1 |
| Wilkinson, K | 1 |
| Rumbles, S | 1 |
| Schofield, G | 1 |
| Kamm, M | 1 |
| Williams, C | 1 |
| Price, A | 1 |
| Talbot, I | 1 |
| Forbes, A | 1 |
| Jess, T | 2 |
| Winther, KV | 2 |
| Munkholm, P | 3 |
| Langholz, E | 3 |
| Binder, V | 3 |
| Lim, WC | 1 |
| Hanauer, SB | 2 |
| Bergman, R | 1 |
| Parkes, M | 1 |
| Rubin, DT | 2 |
| LoSavio, A | 1 |
| Yadron, N | 1 |
| Huo, D | 1 |
| Terdiman, JP | 1 |
| Steinbuch, M | 1 |
| Blumentals, WA | 1 |
| Ullman, TA | 1 |
| Loftus, EV | 1 |
| Velayos, FS | 1 |
| Tremaine, WJ | 1 |
| Zinsmeister, AR | 1 |
| Scott Harmsen, W | 1 |
| Sandborn, WJ | 1 |
| Nielsen, OH | 1 |
| Munck, LK | 1 |
| Pinczowski, D | 1 |
| Ekbom, A | 1 |
| Baron, J | 1 |
| Yuen, J | 1 |
| Adami, HO | 1 |
| Moody, GA | 1 |
| Jayanthi, V | 1 |
| Probert, CS | 1 |
| Mac Kay, H | 1 |
| Mayberry, JF | 1 |
| Lindberg, BU | 1 |
| Broomé, U | 1 |
| Persson, B | 1 |
| Davidsen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Efficacy and Safety of Sulfasalazine in Patients With Metastatic Colorectal Cancer[NCT06134388] | Phase 3 | 50 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | ||
| A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease[NCT01183845] | Phase 4 | 24 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Association of Golimumab Trough Levels With Endoscopic and Histologic Healing in Patients With Ulcerative Colitis[NCT03773445] | 52 participants (Actual) | Observational | 2019-03-01 | Completed | |||
| Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163] | 26 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available) | |||
| An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis[NCT00514982] | Phase 2 | 0 participants (Actual) | Interventional | 2007-08-07 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks
| Intervention | score on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hpynotherapy | 7 |
| UC Patients Given Control Educational Sessions | 10 |
Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 1.5 |
| UC Patients Given Control Educational Sessions | 4 |
IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 195 |
| UC Patients Given Control Educational Sessions | 192 |
Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 0.3 |
| UC Patients Given Control Educational Sessions | 0.4 |
The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 8 |
| UC Patients Given Control Educational Sessions | 7 |
5 reviews available for sulfasalazine and Colorectal Neoplasms
| Article | Year |
|---|---|
Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; | 2015 |
Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Drug Therapy, Co | 2003 |
Controversies with aminosalicylates in inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chemopreventi | 2004 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Drug insight: aminosalicylates for the treatment of IBD.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative; | 2007 |
12 other studies available for sulfasalazine and Colorectal Neoplasms
| Article | Year |
|---|---|
Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Topics: Amino Acid Transport System y+; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell P | 2015 |
Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.
Topics: Adenocarcinoma; Adult; Aged; Cadherins; CDX2 Transcription Factor; Cell Differentiation; Cell Prolif | 2016 |
Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice.
Topics: Angiogenesis Inhibitors; Animals; Cimetidine; Colorectal Neoplasms; Cyclophosphamide; Diclofenac; Di | 2012 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hor | 2004 |
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Case-Control Studies; Chemoprevention; Chronic Disease; Colitis, Ulcera | 2006 |
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colorectal Neoplasms; Female; H | 2007 |
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
Topics: Adult; Case-Control Studies; Colonoscopy; Colorectal Neoplasms; Denmark; Female; Gastrointestinal Ag | 2007 |
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.
Topics: Adolescent; Adult; Case-Control Studies; Cohort Studies; Colitis, Ulcerative; Colorectal Neoplasms; | 1994 |
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cohort Studies; Colectomy; Colitis, Ulcerative; Colorectal Ne | 1996 |
Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Co | 2001 |
Colorectal cancer risk and mortality in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Child; Cohort Studies; Colectomy; | 1992 |